Gao Emily, Hercun Julian, Heller Theo, Vilarinho Sílvia
Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA.
Translational Hepatology Section, National Institute of Diabetes & Digestive & Kidney Diseases, National Institute of Health, Bethesda, MD, USA.
Transl Gastroenterol Hepatol. 2021 Apr 5;6:28. doi: 10.21037/tgh.2020.04.04. eCollection 2021.
The landscape of chronic liver disease has drastically changed over the past 20 years, largely due to advances in antiviral therapy and the rise of metabolic syndrome and associated non-alcoholic fatty liver disease (NAFLD). Despite advances in the diagnosis and treatment of a variety of liver diseases, the burden of chronic liver disease is increasing worldwide. The first step to addressing any disease is accurate diagnosis. Here, we discuss liver diseases that remain undiagnosed, either because they are difficult to diagnose or due to hepatic manifestations of an unrecognized systemic disease. Additionally, their underlying etiology may remain unknown or they represent previously uncharacterized and therefore novel liver diseases. Our goal is to provide a framework for approaching undiagnosed liver diseases which elude standard hepatic diagnostic work-up and whose patterns of disease are often overlooked.
在过去20年里，慢性肝病的格局发生了巨大变化，这主要归因于抗病毒治疗的进展以及代谢综合征和相关非酒精性脂肪性肝病（NAFLD）的增加。尽管在各种肝病的诊断和治疗方面取得了进展，但慢性肝病在全球范围内的负担仍在增加。应对任何疾病的第一步都是准确诊断。在此，我们讨论那些仍未被诊断出来的肝病，其原因要么是难以诊断，要么是由于未被识别的全身性疾病的肝脏表现。此外，它们的潜在病因可能仍然不明，或者它们代表了以前未被描述过的新型肝病。我们的目标是提供一个框架，用于处理那些无法通过标准肝脏诊断检查确诊且疾病模式经常被忽视的未诊断肝病。
